These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9538169)

  • 41. Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis.
    Gioulbasanis I; Patrikidou A; Kitikidou K; Papadimitriou K; Vlachostergios PJ; Tsatsanis C; Margioris AN; Papandreou CN; Mavroudis D; Georgoulias V
    Nutr Cancer; 2012; 64(1):41-7. PubMed ID: 22098075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy.
    Shi HB; Li XD; Jiang JT; Zhao WQ; Ji M; Wu CP
    J Cancer Res Ther; 2014; 10(3):681-5. PubMed ID: 25313760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The value of serum Bcl-2 levels in advanced lung cancer patients.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
    Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer.
    Pan B; Che D; Cao J; Shen J; Jin S; Zhou Y; Liu F; Gu K; Man Y; Shang L; Yu Y
    Biomarkers; 2015; 20(4):232-9. PubMed ID: 26301881
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer.
    Fujiwara H; Suchi K; Okamura S; Okamura H; Umehara S; Todo M; Shiozaki A; Kubota T; Ichikawa D; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Otsuji E
    J Surg Oncol; 2011 Jan; 103(1):62-8. PubMed ID: 21031427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronopharmacology of etoposide given by low dose prolonged infusion in lung cancer patients.
    Yamamoto N; Tamura T; Ohe Y; Oshita F; Kasai T; Kurata T; Shinkai T; Eguchi K; Saijo N
    Anticancer Res; 1997; 17(1B):669-72. PubMed ID: 9066599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapeutic efficacy and pharmacokinetics of cisplatin in patients with non-small cell lung cancer].
    Fukuoka M; Kitajima K; Takada M; Negoro M; Matsui S; Kusunoki K; Ryu Y; Sakai S; Takifuji N; KimuraT
    Nihon Kyobu Shikkan Gakkai Zasshi; 1987 Jan; 25(1):44-9. PubMed ID: 3037144
    [No Abstract]   [Full Text] [Related]  

  • 48. Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.
    Vlachostergios PJ; Gioulbasanis I; Ghosh S; Tsatsanis C; Papatsibas G; Xyrafas A; Hatzidaki E; Vasiliou C; Kamposioras K; Agelaki S; Margioris AN; Nasi D; Georgoulias V; Papandreou CN
    Clin Transl Oncol; 2013 Nov; 15(11):903-9. PubMed ID: 23463594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Inhibitor of apoptosis in lung cancer Livin perioperative clinical research].
    Wang LN; Mou J; Zhang YB; Dong P; Diao X; Wang SY; Chen H; Liu YF
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Sep; 26(9):889-90. PubMed ID: 20815986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A study of IL-2 activity on lung cancer].
    Wang YZ
    Zhonghua Jie He He Hu Xi Za Zhi; 1991 Aug; 14(4):216-8, 255. PubMed ID: 1666344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.
    De Vita F; Orditura M; Galizia G; Romano C; Roscigno A; Lieto E; Catalano G
    Chest; 2000 Feb; 117(2):365-73. PubMed ID: 10669676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer.
    Song XY; Zhou SJ; Xiao N; Li YS; Zhen DZ; Su CY; Liu ZD
    Asian Pac J Cancer Prev; 2013; 14(8):4765-8. PubMed ID: 24083740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer.
    Naumnik W; Naumnik B; Niklińska W; Ossolińska M; Chyczewska E
    Adv Exp Med Biol; 2016; 952():41-49. PubMed ID: 27573644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating levels of soluble intercellular adhesion molecule-1 in non-small cell lung cancer patients.
    De Vita F; Infusino S; Auriemma A; Orditura M; Catalano G
    Oncol Rep; 1998; 5(2):393-6. PubMed ID: 9468565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis.
    Orditura M; De Vita F; Catalano G; Infusino S; Lieto E; Martinelli E; Morgillo F; Castellano P; Pignatelli C; Galizia G
    J Interferon Cytokine Res; 2002 Nov; 22(11):1129-35. PubMed ID: 12513912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Chemotherapy of non-small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas and nitric oxide (NO) levels].
    Zhou J; Zhu Q; Yao H
    Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):225-7. PubMed ID: 11778237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of interferon-gamma, interleukin-6, and tumor necrosis factor-alpha in the radiation response of patients diagnosed with locally advanced non-small-cell lung cancer and glioblastoma multiforme.
    Deniz ÇD; Gürbilek M; Koç M
    Turk J Med Sci; 2018 Feb; 48(1):117-123. PubMed ID: 29479968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma.
    Diakowska D; Markocka-Maczka K; Grabowski K; Lewandowski A
    Exp Oncol; 2006 Dec; 28(4):319-22. PubMed ID: 17285118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lung cancer: moving forward with tailored strategies.
    Barlesi F
    Lancet Oncol; 2008 Dec; 9(12):1116-7. PubMed ID: 19038756
    [No Abstract]   [Full Text] [Related]  

  • 60. Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients.
    Javid J; Mir R; Julka PK; Ray PC; Saxena A
    Tumour Biol; 2015 Jun; 36(6):4253-60. PubMed ID: 25578497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.